- Home
- VBNK vs ATXS Comparison
VBNK vs ATXS Comparison
Compare VBNK & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBNK
- ATXS
- Stock Information
- Founded
- VBNK 1980
- ATXS 2008
- Country
- VBNK Canada
- ATXS United States
- Employees
- VBNK N/A
- ATXS N/A
- Industry
- VBNK Commercial Banks
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- VBNK Finance
- ATXS Health Care
- Exchange
- VBNK Nasdaq
- ATXS Nasdaq
- Market Cap
- VBNK 441.5M
- ATXS 401.2M
- IPO Year
- VBNK 2021
- ATXS 2015
- Fundamental
- Price
- VBNK $9.05
- ATXS $4.65
- Analyst Decision
- VBNK Strong Buy
- ATXS Strong Buy
- Analyst Count
- VBNK 3
- ATXS 5
- Target Price
- VBNK $19.00
- ATXS $26.60
- AVG Volume (30 Days)
- VBNK 77.0K
- ATXS 283.3K
- Earning Date
- VBNK 03-05-2025
- ATXS 05-08-2025
- Dividend Yield
- VBNK 0.73%
- ATXS N/A
- EPS Growth
- VBNK N/A
- ATXS N/A
- EPS
- VBNK 0.89
- ATXS N/A
- Revenue
- VBNK $75,813,751.00
- ATXS N/A
- Revenue This Year
- VBNK $31.26
- ATXS N/A
- Revenue Next Year
- VBNK $40.97
- ATXS N/A
- P/E Ratio
- VBNK $13.99
- ATXS N/A
- Revenue Growth
- VBNK N/A
- ATXS N/A
- 52 Week Low
- VBNK $9.48
- ATXS $5.05
- 52 Week High
- VBNK $18.38
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- VBNK 26.02
- ATXS 26.05
- Support Level
- VBNK $9.76
- ATXS $5.24
- Resistance Level
- VBNK $10.41
- ATXS $5.60
- Average True Range (ATR)
- VBNK 0.31
- ATXS 0.32
- MACD
- VBNK 0.03
- ATXS -0.11
- Stochastic Oscillator
- VBNK 4.30
- ATXS 1.10
About VBNK VersaBank
VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.